“This acquisition allows us to leverage Courante’s extensive experience in oncology trials and enhance our capabilities in managing global studies.”
Dr. Bertagnolli is a surgical oncologist, cancer researcher, educator, and current director of the National Cancer Institute (NCI). She previously served as the Richard E. Wilson Professor of Surgery in the field of surgical oncology at Harvard Medical School, a surgeon at Brigham and Women’s Hospital, and a member of the Gastrointestinal Cancer Treatment and Sarcoma Centers at Dana-Farber Cancer Institute.
On the cusp of artificial intelligence (AI) becoming a ubiquitous feature of our everyday lives, researchers discover that intelligent systems thinking offers a wealth of potential applications in the fight against a cunning human adversary: Cancer.
The PCR and real-time PCR molecular diagnostics was valued at $4 billion in 2019.
Although the medtech industry is expected to enjoy steady growth, device companies are still challenged to attract the skilled labor that manufacturing requires.
Economic development in China has created a burgeoning middle class that demands higher standards of living.
Contributing factors include a change in lifestyle, an increase in wealth, and chronic infections in rural regions.